Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
KYOWA KIRIN CO. LTD. |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 2604.00 JPY | -1.42% | -2.22% | -13.77% | |
| Sep. 25 | Sector Update: Health Care Stocks Flat to Lower Pre-Bell Monday | MT |
| Sep. 25 | Ardelyx Says Partner Received Approval for Tenapanor to Treat Hyperphosphatemia in Japan | MT |
| Sales 2023 * | 430 B 2,888 M | Sales 2024 * | 434 B 2,916 M | Capitalization | 1420 B 9 533 M |
|---|---|---|---|---|---|
| Net income 2023 * | 71,697 M 481 M | Net income 2024 * | 73,443 M 493 M | EV / Sales 2023 * | 2,47x |
| Net cash position 2023 * | 357 B 2,395 M | Net cash position 2024 * | 389 B 2,612 M | EV / Sales 2024 * | 2,37x |
| P/E ratio 2023 * | 19,7x | P/E ratio 2024 * | 19,3x | Employees | - |
| Yield 2023 * | 2,05% | Yield 2024 * | 2,20% | Free-Float | 45.89% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.42% | ||
| 1 week | -2.05% | ||
| Current month | -2.49% | ||
| 1 month | -1.92% | ||
| 3 months | -2.89% | ||
| 6 months | -9.58% | ||
| Current year | -13.77% |
1 week
2 559.00
2 703.00
1 month
2 559.002 742.50
Current year
2 529.503 150.00
1 year
2 529.503 515.00
3 years
2 529.504 240.00
5 years
1 674.004 240.00
10 years
985.004 240.00
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.51% | 2 M$ | +1.26% | - | |
| 0.44% | 4 M$ | +12.89% | - | |
| 0.41% | 312 M$ | +20.00% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-09-29 | 2604.00 | -1.42% | 1 885 500 |
| 23-09-28 | 2641.50 | -1.25% | 916,900 |
| 23-09-27 | 2675.00 | +0.91% | 972,300 |
| 23-09-26 | 2651.00 | -1.81% | 708,100 |
| 23-09-25 | 2700.00 | +1.56% | 825,300 |
Delayed Quote Japan Exchange, September 29, 2023 at 02:00 am EDT
More quotes
Kyowa Kirin Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows:
- sales of pharmaceutical products (92.6%): prescription products for anemia, cancers, immune and nephrology diseases treatment;
- sales of licenses (7.4%).
At the end of 2021, the group had 3 production sites located in Japan (2) and China.
Net sales break down geographically as follows: Japan (60.9%), Asia (9%), Americas (16.3%) and Europe (13.8%).
Sector
Pharmaceuticals
Calendar
2023-10-30
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
2641.50JPY
Average target price
3227.27JPY
Spread / Average Target
+22.18%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -13.77% | 9 508 M $ | |
| +53.51% | 73 M $ | |
| +68.79% | 846 M $ | |
| -38.26% | 103 M $ | |
| +67.38% | 2 539 M $ | |
| +55.64% | 190 M $ | |
| -30.17% | 689 M $ | |
| -14.49% | 266 M $ | |
| +19.56% | 4 998 M $ | |
| +32.52% | 3 998 M $ |
